Glycopirronium Medical Valley (Glycopyrronium Bromide)

Glycopirronium Medical Valley is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) and for relief of bronchospasm associated with asthma.

• Long‑acting bronchodilation to improve airflow in patients with COPD.
• Reduction of bronchoconstriction during asthma exacerbations.
• Use as part of a comprehensive COPD management plan that may include inhaled corticosteroids or long‑acting β2‑agonists.
• May be prescribed for patients who require an anticholinergic agent when other bronchodilators are insufficient.
• Can be administered once daily as directed by a healthcare professional.

Side effects reported with inhaled glycopyrronium bromide vary in frequency and severity.

Common

• Dry mouth or altered taste sensation.
• Cough or throat irritation after inhalation.
• Upper respiratory tract infection symptoms.
• Headache or mild dizziness.

Serious

• Paradoxical bronchospasm requiring immediate medical attention.
• Severe allergic reactions such as rash, angioedema, or anaphylaxis.
• Rapid heart rate or arrhythmia in susceptible individuals.

Before initiating Glycopirronium Medical Valley, clinicians should evaluate several safety considerations to minimize risk.

• Assess for known hypersensitivity to glycopyrronium bromide or other anticholinergic agents.
• Use cautiously in patients with narrow-angle glaucoma or urinary retention.
• Monitor cardiac function in individuals with pre‑existing arrhythmias or coronary disease.
• Evaluate renal or hepatic impairment, as drug clearance may be altered.
• Advise patients to avoid abrupt discontinuation without medical guidance.
• Consider pregnancy and lactation status; safety data are limited.

Glycopirronium Medical Valley may interact with other medications that affect the cholinergic system or cardiovascular function.

Avoid

• Concurrent use of other anticholinergic inhalers (e.g., ipratropium) without dose adjustment.
• Strong CYP3A4 inhibitors that could increase systemic exposure.
• Medications that prolong the QT interval when combined with glycopyrronium.

Use with caution

• Beta‑agonists or theophylline, as combined bronchodilation may increase heart rate.
• Diuretics, because anticholinergic effects can reduce urinary output.
• Drugs affecting ocular pressure in patients with glaucoma.